BFRI

NASD Biofrontera, Inc.

Oct 28, 2026 · 12:16 AM ET EOD Market Closed

$0.8398 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.8398, $0.0227 below the day’s high of $0.8625

YTD change: +47.33%
vs 20-day SMA: -6.64%
vs 200-day SMA: -18.66%

Price ranges

Previous day

$0.7800 $0.8260

open $0.7900 close $0.8220

+$0.0320 (+4.05%)

Today

$0.8010 $0.8625

open $0.8250 now $0.8398

+$0.0148 (+1.79%)

Past week

$0.7800 $0.8299

from $0.8057 now $0.8398

+$0.0341 (+4.23%)

Past month

$0.7800 $1.1400

from $1.1300 now $0.8398

-$0.2902 (-25.68%)

This year

$0.5700 $1.6600

from $0.5700 now $0.8398

+$0.2698 (+47.33%)

Price & Performance

-0.29 (-25.68%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral

The stock is 99.7% away from all-time highs of $292.6000
BFRI is up 47% since the beginning of the year
BFRI is down 18% over the past 12 months
BFRI is down 26% over the past 1 month
1% of all BFRI investors are betting against BFRI

BFRI reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is -18.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.05

Earnings momentum +77.3% Quarterly EPS growth

Quarterly change +77.3%

Valuation

P/E ratio N/A

Enterprise value $13.5M

Beta 0.28

Balance sheet & scale

IncomeN/A

Revenue$46.2M

Cash$4.7M

Debt$7.5K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $12.5M

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,281.91	+0.22%
JNJ	Johnson & Johnson	$268.73	+0.91%
ABBV	AbbVie, Inc.	$286.39	-0.12%
MRK	Merck & Co., Inc.	$141.82	+0.86%
RHHBY	Roche Holding Ltd Sponsored ADR	$60.37	+0.65%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.